Clinical Trials Logo

HER2 Negative Breast Carcinoma clinical trials

View clinical trials related to HER2 Negative Breast Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02157051 Active, not recruiting - Clinical trials for Stage IV Breast Cancer

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

Start date: June 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine in treating patients with human epidermal growth factor receptor 2 (HER2)-negative stage III-IV breast cancer. Multiantigen DNA plasmid-based vaccine may target immunogenic proteins expressed in breast cancer stem cells which are the component of breast cancer that is resistant to chemotherapy and has the ability to spread. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells.